Comparing PCSK9 inhibitor prescription rates within high-risk populations: diabetes mellitus, multi-territory vascular disease, multivessel and recurrent coronary artery disease
Event:
ESC Congress 2024
Topic:
Secondary Prevention
Session:
Lifestyle, obesity, and dyslipidaemia